Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Metwalli Website

Adam R. Metwalli, M.D.

Selected Publications

1)  Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM.
Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.
J. Clin. Oncol. 32: 431-7, 2014.
2)  Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM.
The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management.
Urology. [Epub ahead of print], 2014.
3)  Farley MN, Schmidt LS, Mester JL, Peña-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie XJ, Dahia PL, Eng C, Linehan WM, Brugarolas J.
A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.
Mol. Cancer Res. 11: 1061-71, 2013.
4)  Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM.
Clinical Significance of Ureteral 'Skip Lesions' at the Time of Radical Cystectomy: the Md-Anderson Experience and Review of Literature.
BJU Int. [Epub ahead of print], 2013.
5)  Metwalli AR, Pinto PA.
Commentary on: "Focal cryosurgical ablation of the prostate: a single institute"s perspective".
BMC Urol. 13: 39, 2013.
6)  Stamatakis L, Metwalli AR, Middelton LA, Marston Linehan W.
Diagnosis and management of BHD-associated kidney cancer.
Fam. Cancer. 12: 397-402, 2013.
7)  Shuch B, Ricketts CJ, Vocke CD, Komiya T, Middelton LA, Kauffman EC, Merino MJ, Metwalli AR, Dennis P, Linehan WM.
Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer.
J. Urol. 190: 1990-8, 2013.
8)  Vourganti S, Harbin A, Singer EA, Shuch B, Metwalli AR, Agarwal PK.
Low Grade Micropapillary Urothelial Carcinoma, Does It Exist? - Analysis of Management and Outcomes from the Surveillance, Epidemiology and End Results (SEER) Database.
J Cancer. 4: 336-42, 2013.
9)  Agochukwu NQ, Metwalli AR, Kutikov A, Pinto PA, Linehan WM, Bratslavsky G.
Economic burden of repeat renal surgery on solitary kidney--do the ends justify the means? A cost analysis.
J. Urol. 188: 1695-700, 2012.
10)  Volkin D, Yerram N, Ahmed F, Lankford D, Baccala A, Gupta GN, Hoang A, Nix J, Metwalli AR, Lang DM, Bratslavsky G, Linehan WM, Pinto PA.
Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome.
J. Pediatr. Surg. 47: 2077-82, 2012.
11)  Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, Yang Y, Wei MH, Pautler SE, Peterson J, Stolle CA, Zbar B, Merino MJ, Schmidt LS, Pinto PA, Srinivasan R, Pacak K, Linehan WM.
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.
J. Urol. 188: 2063-71, 2012.
12)  Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM.
Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
Cancer Biol. Ther. 10: 885-92, 2010.
13)  Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, Agarwal PK, McConkey DJ, Hazle JD, Dinney CP.
Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis.
BJU Int. 106: 1799-804, 2010.
14)  Rogers CG, Metwalli A, Blatt AM, Bratslavsky G, Menon M, Linehan WM, Pinto PA.
Robotic partial nephrectomy for renal hilar tumors: a multi-institutional analysis.
J. Urol. 180: 2353-6; discussion 2356, 2008.
15)  Dozmorov MG, Yang Q, Matwalli A, Hurst RE, Culkin DJ, Kropp BP, Lin HK.
5alpha-androstane-3alpha,17beta-diol selectively activates the canonical PI3K/AKT pathway: a bioinformatics-based evidence for androgen-activated cytoplasmic signaling.
Genomic Med. 1: 139-46, 2007.
16)  Hadaschik BA, Black PC, Sea JC, Metwalli AR, Fazli L, Dinney CP, Gleave ME, So AI.
A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging.
BJU Int. 100: 1377-84, 2007.
17)  Metwalli AR, Kamat AM.
Controversial issues and optimal management of stage T1G3 bladder cancer.
Expert Rev Anticancer Ther. 6: 1283-94, 2006.
18)  Fung KM, Samara EN, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JV, Culkin DJ, Kropp BP, Penning TM, Lin HK.
Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Endocr. Relat. Cancer. 13: 169-80, 2006.
19)  Li X, Wong C, Mysel R, Slobodov G, Metwalli A, Kruska J, Manatt CS, Culkin DJ, Kropp BP, Lin HK.
Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization.
Mol. Cancer. 4: 30, 2005.
20)  Metwalli AR, Colvert JR, Kropp BP.
Tissue engineering in urology: where are we going?.
Curr Urol Rep. 4: 156-63, 2003.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/10/2014.